Hawaii Biotech

Hawaii Biotech, Inc., established in 1982 and based in Aiea, Hawaii, is a biotechnology company specializing in the research and development of prophylactic vaccines for infectious diseases. It offers a recombinant protein production platform, applicable to manufacturing vaccines, diagnostic kits, and research tools. The company's vaccine pipeline includes targets such as West Nile, dengue, influenza, hepatitis C, malaria, Japanese encephalitis, Ebola, and Eastern equine encephalitis. Additionally, Hawaii Biotech develops recombinant subunit protein vaccines, focusing on the quality of recombinant protein produced and its impact on immunogenicity, and GPI-0100, a saponin adjuvant to enhance immune responses, particularly in cancer therapies.